X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8819) 8819
Book Review (1244) 1244
Publication (891) 891
Newsletter (403) 403
Book Chapter (44) 44
Magazine Article (23) 23
Book / eBook (13) 13
Conference Proceeding (9) 9
Dissertation (6) 6
Data Set (3) 3
Newspaper Article (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8150) 8150
humans (6626) 6626
pharmacology & pharmacy (4976) 4976
male (3777) 3777
animals (2981) 2981
cytochrome p-450 enzyme system - metabolism (2677) 2677
cytochrome p-450 (2664) 2664
female (2548) 2548
cytochrome p-450 cyp3a (2332) 2332
metabolism (2295) 2295
drug interactions (2275) 2275
pharmacokinetics (2188) 2188
adult (1912) 1912
cytochrome p-450 cyp3a - metabolism (1827) 1827
rats (1528) 1528
middle aged (1507) 1507
cytochrome p450 (1503) 1503
cytochrome p-450 enzyme inhibitors (1408) 1408
toxicology (1355) 1355
in-vitro (1282) 1282
microsomes, liver - enzymology (1143) 1143
physiological aspects (1114) 1114
enzymes (1109) 1109
cytochrome p-450 cyp3a - genetics (1071) 1071
microsomes, liver - metabolism (1044) 1044
enzyme inhibitors - pharmacology (1034) 1034
cytochrome p-450 enzyme system - genetics (1023) 1023
liver (1022) 1022
analysis (965) 965
research (950) 950
cyp3a4 (939) 939
inhibition (917) 917
microsomes, liver - drug effects (893) 893
expression (891) 891
p-glycoprotein (885) 885
dose-response relationship, drug (876) 876
genotype (843) 843
cytochrome p-450 cyp3a inhibitors (827) 827
area under curve (824) 824
human liver-microsomes (823) 823
aged (816) 816
biochemistry & molecular biology (775) 775
induction (751) 751
kinetics (746) 746
metabolites (743) 743
pharmacology/toxicology (740) 740
biotransformation (732) 732
liver - enzymology (728) 728
pharmacogenetics (707) 707
rats, sprague-dawley (693) 693
mice (660) 660
administration, oral (657) 657
liver - drug effects (631) 631
liver - metabolism (628) 628
pharmacology (624) 624
drug-interactions (592) 592
young adult (581) 581
hydroxylation (567) 567
aryl hydrocarbon hydroxylases (540) 540
aryl hydrocarbon hydroxylases - metabolism (540) 540
chemistry, medicinal (523) 523
in vitro techniques (522) 522
mixed function oxygenases - metabolism (522) 522
abridged index medicus (514) 514
cancer (508) 508
cyp3a (508) 508
chromatography, high pressure liquid (501) 501
drugs (493) 493
drug metabolism (488) 488
drug-metabolism (478) 478
ketoconazole (477) 477
midazolam (476) 476
genetic aspects (473) 473
identification (463) 463
cross-over studies (458) 458
adolescent (451) 451
cytochrome (449) 449
oncology (446) 446
ketoconazole - pharmacology (443) 443
biomedicine (434) 434
polymorphism, genetic (431) 431
article (419) 419
drug therapy (417) 417
isoenzymes - metabolism (417) 417
cells, cultured (415) 415
models, biological (415) 415
cytochrome p-450 enzyme system - biosynthesis (413) 413
drug-drug interactions (403) 403
rat (403) 403
time factors (399) 399
medicine & public health (398) 398
microsomes (389) 389
hepatocytes - drug effects (384) 384
tacrolimus (383) 383
health aspects (379) 379
aryl hydrocarbon hydroxylases - genetics (378) 378
oxidoreductases, n-demethylating - metabolism (371) 371
biological availability (368) 368
gene expression (363) 363
cytochrome p-450 cyp2d6 - metabolism (362) 362
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9164) 9164
Spanish (31) 31
Chinese (29) 29
German (15) 15
Japanese (14) 14
French (12) 12
Russian (6) 6
Hungarian (3) 3
Dutch (2) 2
Norwegian (2) 2
Polish (2) 2
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2016, Volume 44, Issue 8, pp. 1217 - 1228
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 02/2015, Volume 43, Issue 2, pp. 182 - 189
Evaluation of drug-drug interaction (DDI) involving circulating inhibitory metabolites of perpetrator drugs has recently drawn more attention from regulatory... 
IN-VITRO | WARFARIN | KINETICS | HUMANS | PHARMACOLOGY & PHARMACY | PLASMA-PROTEIN BINDING | DESETHYLAMIODARONE | DISCOVERY | DIALYSIS | Cytochrome P-450 CYP2D6 Inhibitors - chemistry | Liver - enzymology | Cytochrome P-450 CYP2D6 Inhibitors - metabolism | Expert Systems | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP2C9 Inhibitors - chemistry | Amiodarone - blood | Anti-Arrhythmia Agents - metabolism | Amiodarone - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Liver - drug effects | Amiodarone - pharmacokinetics | Computer Simulation | Cytochrome P-450 CYP3A Inhibitors - chemistry | Cytochrome P-450 CYP2C9 Inhibitors - metabolism | Adult | Female | Cytochrome P-450 CYP2C9 Inhibitors - blood | Reproducibility of Results | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - blood | Administration, Oral | Liver - metabolism | Amiodarone - antagonists & inhibitors | Anti-Arrhythmia Agents - chemistry | Anti-Arrhythmia Agents - pharmacokinetics | Anti-Arrhythmia Agents - administration & dosage | Amiodarone - analogs & derivatives | Amiodarone - metabolism | Cytochrome P-450 CYP3A Inhibitors - metabolism | Models, Biological | Biotransformation - drug effects | Cytochrome P-450 CYP2D6 Inhibitors - blood | Infusions, Intravenous | Cytochrome P-450 CYP2C9 Inhibitors - pharmacokinetics | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6678 - 6692
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers.... 
TARGET | CHEMISTRY, MEDICINAL | PATHWAY | MECHANISMS | BETA-CATENIN | WNT | CANCER | Acyltransferases - antagonists & inhibitors | Maleimides - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Microsomes, Liver - metabolism | Maleimides - pharmacology | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Maleimides - pharmacokinetics | Cytochrome P-450 CYP1A2 Inhibitors - pharmacokinetics | Maleimides - chemical synthesis | HEK293 Cells | Pyridazines - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - pharmacology | Wnt Signaling Pathway | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Rats | Cytochrome P-450 CYP1A2 Inhibitors - chemical synthesis | Cytochrome P-450 CYP2D6 Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - chemical synthesis | Xenograft Model Antitumor Assays | Animals | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - chemical synthesis | High-Throughput Screening Assays | Membrane Proteins - antagonists & inhibitors | Mice, Nude | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Cell Line, Tumor | Pyridazines - pharmacokinetics | Mice, Inbred BALB C | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 03/2010, Volume 38, Issue 3, pp. 448 - 458
Journal Article
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 7/2018, Volume 74, Issue 7, pp. 913 - 920
Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of... 
Biomedicine | Inter-racial variability | Caucasian | South Asian | Pharmacology/Toxicology | Pharmacokinetics | Inducibility | Cytochrome P450 3A4 | MESSENGER-RNA EXPRESSION | INTERINDIVIDUAL VARIABILITY | POPULATIONS | POLYMORPHISM | CYTOCHROME-P450 3A4 | GENOTYPE-PHENOTYPE ASSOCIATIONS | METABOLISM | IN-VIVO | PHARMACOLOGY & PHARMACY | MIDAZOLAM | Rifampin - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Rifampin - blood | Area Under Curve | Humans | Asian Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP3A Inducers - blood | Clarithromycin - blood | Young Adult | Cytochrome P-450 CYP3A - genetics | Clarithromycin - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Adult | Continental Population Groups | European Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - blood | Enzyme Induction | Genotype | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacology | Midazolam - blood | Cytochrome P-450 CYP3A - metabolism | Rifampin - pharmacology | Clarithromycin - pharmacology | Physiological aspects | Medical colleges | Rifampin | Analysis | Cytochrome P-450 | Cytochrome | Clarithromycin | Statistical analysis | Cytochrome P450 | Variability | Whites | Exposure | Males | Metabolism | Substrates | Midazolam | Genotypes | Asians | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Cabozantinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid... 
pharmacokinetics | CYP2C8 | drug–drug interaction | CYP3A4 | cabozantinib | drug-drug interaction | XL184 | ERYTHROMYCIN | SUNITINIB | PHARMACOLOGY & PHARMACY | SORAFENIB | 6-BETA-HYDROXYCORTISOL | Rifampin - pharmacokinetics | Area Under Curve | Ketoconazole - administration & dosage | Humans | Microsomes, Liver - metabolism | Half-Life | Pyridines - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Anilides - pharmacokinetics | Antineoplastic Agents - administration & dosage | Thiazolidinediones - pharmacokinetics | Hypoglycemic Agents - blood | Drug Interactions | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Microsomes, Liver - enzymology | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ketoconazole - pharmacokinetics | Anilides - blood | Cytochrome P-450 CYP3A Inducers - administration & dosage | Pyridines - blood | Anilides - administration & dosage | Antineoplastic Agents - blood | Thiazolidinediones - blood | Dosage and administration | Ketoconazole | Pharmacokinetics | Rifampin | Analysis | Drug interactions | Plasma | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2010, Volume 160, Issue 4, pp. 919 - 930
Background and purpose:  The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the... 
CYP3A | drug-drug interactions | CYP2D6 | pharmacodynamics | oxycodone | oxymorphone | experimental pain | genetic polymorphism | drug–drug interactions | Pharmacodynamics | Oxycodone | Genetic polymorphism | Experimental pain | Drug-drug interactions | Oxymorphone | MORPHINE | CONTROLLED-RELEASE OXYCODONE | P-GLYCOPROTEIN | PAIN | METABOLISM | PHARMACOKINETICS | IN-VIVO | ORAL OXYCODONE | PHARMACOLOGY & PHARMACY | CODEINE | RECEPTOR-BINDING | Cytochrome P-450 CYP2D6 Inhibitors | Humans | Middle Aged | Analgesics, Opioid - pharmacology | Male | Young Adult | Analgesics, Opioid - adverse effects | Drug Interactions | Pain Threshold - drug effects | Adult | Oxycodone - adverse effects | Metabolic Detoxication, Phase I - genetics | Oxymorphone - blood | Cytochrome P-450 CYP2D6 - genetics | Oxycodone - therapeutic use | Reflex, Pupillary - drug effects | Oxycodone - pharmacology | Double-Blind Method | Enzyme Inhibitors - pharmacology | Analgesics, Opioid - therapeutic use | Genotype | Psychomotor Performance - drug effects | Polymorphism, Genetic | Cross-Over Studies | Oxycodone - pharmacokinetics | Phenotype | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP3A - metabolism | Analgesics, Opioid - pharmacokinetics | Cytochrome P-450 CYP2D6 - metabolism | Drug therapy | Enzymes | Pain | Pain perception | Ketoconazole | Toxicity | Cytochrome P450 | Gene polymorphism | Electrical stimuli | Side effects | Analgesics | Metabolites | Quinidine | Drug interaction | Oxidation | Pharmacokinetics | CYP2D6 protein | Index Medicus | Research Papers
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2017, Volume 83, Issue 9, pp. 1954 - 1965
Journal Article
Environmental Pollution, ISSN 0269-7491, 03/2017, Volume 222, pp. 504 - 512
Journal Article